Overview

  • Under Development, FDA Approval Required.
  • Available On-Demand bio-medicine targeting tumor-associated antigens.
  • Will work for many breast cancer patients.
  • Delivered through intranodal injection
  • Engineered with next-generation sequencing and artificial intelligence.

Status

  • Pre-Clinical Feasibility
  • Gene Sequencing Clinical Study
  • Phase I Clinical Study